Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio [Yahoo! Finance]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Yahoo! Finance
for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications. This application follows the U.S. Provisional Application No. 63/440,890 which was filed on January 24, 2023. The patent application titled “Treatment of Mental Illness via Administration of Buntanetap and Analogues Thereof” addresses methods for treating, inhibiting, reducing, slowing, or delaying onset of mental illnesses by administration of buntanetap or its pharmaceutically acceptable salts. Buntanetap can be used alone or synergistically with effective quantities of antipsychotic agents, antidepressant agents, hallucinogenic agents, or combinations thereof. This patent application addresses mental illnesses such as autism, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, anxiety, and schizophrenia, which have been shown to share similar pathological abnormalities
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders [Yahoo! Finance]Yahoo! Finance
- Annovis Bio CEO Maria Maccecchini Issues Letter to StockholdersGlobeNewswire
- Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market [Seeking Alpha]Seeking Alpha
- Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects [Seeking Alpha]Seeking Alpha
- Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question [Seeking Alpha]Seeking Alpha
ANVS
Earnings
- 8/14/23 - Beat
ANVS
Sec Filings
- 5/6/24 - Form DEFA14A
- 5/6/24 - Form 8-K
- 5/2/24 - Form 8-K
- ANVS's page on the SEC website